microRNA在脆性X综合征发病机制中的研究进展

脆性X综合征(fragile X syndrome,FXS)是最常见的遗传性认知障碍疾病,也是一种与自闭症谱系障碍(autism spectrum disorder,ASD)相关的严重的基因疾病.它主要是由于脆性X智力低下基因1(fragile X mental retardation 1,FMR1)的异常扩增及其上游Cp G岛的异常甲基化,导致其编码的脆性X智力低下蛋白(fragile X mental retardation protein,FMRP)表达减少或缺失引起的.FMRP与miRNA(micro RNA)均具有翻译抑制活性,而且FMRP在生物化学和遗传学上均与miRNA调控通路有相互作用.此外,越来越多的研究发现miRNA调控通路在FXS的发病和治疗中发挥作用.因此,本文对miRNA的功能及其与脆性X蛋白家族成员间的相互作用进行阐述,为在miRNA水平了解FXS的发病机制奠定基础.     

整合分析脆性X染色体综合征患者来源的诱导多能干细胞在神经元分化中的转录组变化

脆性X染色体综合征(fragile X syndrome,FXS)患者在FMR1基因的启动子区具有超过200个以上CGG三核苷酸重复片段,导致其编码的脆性X智力低下蛋白(fragile X mental retardation protein,FMRP)的表达减少或缺失.然而目前尚未在单核苷酸分辨率(即RNA-seq)水平上鉴定FMRP缺失所引起的转录组变化.本文对FXS患者成纤维细胞来源的诱导多能干细胞(human induced pluripotent stem cell,iPS细胞)(FXS-iPSC)进行了体外神经元分化.然后釆用RNA-seq技术检测了FXS-iPSC在体外神经元分化各阶段的转录调控变化情况.通过详尽的分析这些转录组数据并整合其他研究平台的成果,发现在FXS-iPSC分化得到的神经元中许多与神经元分化相关的转录因子(WNT1,BMP4,POU3F4,TFAP2C和PAX3)表达上调,钾离子通道基因(KCNA1,KCNC3,KCNG2,KCNIP4,KCNJ3,KCNK9和KCNT1)表达下调,而SHANK1和NNAT转录调控的时序发生改变,这表明FXS患者神经元的分化和功能受损.综上所述,本研究证明FXS患者中FMRP的缺失显著影响了神经发育过程的基因表达模式,并将有助于发现临床治疗FXS的潜在靶点.     

非编码RNA与X脆性综合征

X脆性综合征（fragile X syndrome,FXS）是由X脆性智力低下1（FMR1）基因5＇端非翻译区CGG重复序列的异常扩增,导致X脆性智力低下蛋白（FMRP）缺失引起的.非编码RNA是除编码蛋白质的mRNAs以外的其他所有RNA分子,已被发现在中枢神经系统中具有重要的作用,如微RNA与BC1/BC200 RNA参与了X脆性智力低下蛋白的翻译抑制.认识非编码RNA与X脆性综合征的关系不但能加深对X脆性综合征的分子机制的理解,而且有助于揭示学习与记忆的奥秘.     

脆性X智力低下蛋白参与非编码RNA通路的研究进展

脆性X综合征(Fragile X syndrome)是一种最常见的遗传性智力低下疾病,并且伴有语言和行为障碍等。该疾病是由脆性X智力低下基因(Fragile X mental retardation 1, FMR1)突变而导致脆性X智力低下蛋白(Fragile X mental retardation protein, FMRP)表达异常造成的。近年来,研究发现FMRP参与非编码RNA通路,并发挥多种重要生物学功能,这对理解脆性X综合征发病机理具有重要的推动作用。首先发现FMRP与siRNA和miRNA通路中Dicer酶、Ago1和Ago2蛋白相互作用,参与神经活动及生殖干细胞命运决定等重要过程。随后又发现FMRP与piRNA通路中Aub、Ago1和Piwi蛋白相互作用,维持了染色体正常结构和基因组稳定性。最新研究结果发现FMRP与lncRNA相互作用,其功能和价值正引起关注。本文从FMRP与非编码RNA通路的关系展开,着重介绍了FMRP与piRNA之间的相互作用,以期为深入理解非编码RNA通路在脆性X综合征的发病过程中作用提供参考,同时期望与临床医学领域尽快形成交叉研究,早日促进理论成果转化为临床应用。     

关于mGluR在脆性X综合征发病机制中的研究新进展

脆性X综合征为最常见的遗传性智力低下性疾病之一,是由于FMR1基因异常导致其编码的脆性X智力低下蛋白减少或缺失所致.研究发现脆性X综合征尸解病人和FMR1基因敲除小鼠(KO鼠)神经元树突棘发育不成熟,模型小鼠海马区代谢性谷氨酸受体所触发的长时程抑制(LTD)延长,不成熟的树突棘导致突触功能障碍被认为是脑功能异常的基础.最近的研究表明,应用代谢性谷氨酸受体拮抗剂能改善由FMRP缺失所导致的突触和行为缺陷,表明mGluR功能过度激活可能参与了脆性X综合征的发病过程,但具体机制不明.FMRP是一种mRNA结合蛋白,可作为翻译抑制因子负性调节突触后膜mRNA的翻译和表达.因此推测FMRP缺乏和减少可能导致mGluR激发的mRNA翻译增多,参与神经系统发育的蛋白过度表达,而影响树突棘的发育,但具体机制仍不清楚.本文对mGluR和脆性X综合征的研究历史和最新进展进行了讨论.     

脆性X综合征FMRP缺失对离子通道的异常调控

脆性X综合征(FXS)由脆性X智力低下蛋白FMRP表达降低甚至完全缺失引起,是最常见的遗传性智力缺陷综合征和孤独症谱系障碍的单基因致病因素。FMRP不仅可与离子通道mRNA结合,如电压门控钾通道(Kv3.1和Kv4.2)等,还直接与多个离子通道作用,如钠激活钾通道(Slack)等。FMRP的缺失导致神经元离子通道表达异常和功能失调,在不同的脑区和不同的神经细胞类型中引起特定的离子稳态失衡、膜电位改变和兴奋性失常,导致神经环路过度兴奋。现就FMRP缺失对不同离子通道的异常调控及其研究进展进行综述。     

智力低下相关蛋白(FXR1P)与CMAS相互作用的生物学效应研究

脆性X综合征(FXS)是一种遗传性智力低下疾病,其发病率仅次于21三体综合征．脆性X智力低下蛋白(FMRP)是FXS的关键性致病因子,该蛋白由脆性X智力低下基因1(FMR1)编码所得．FMR1在神经肌肉和睾丸组织中广泛表达．脆性X相关蛋白1(FXR1P)则是由FMR1的同源基因脆性X相关基因1(FXR1)编码所得,并且与蛋白质和RNAs之间存在着相互作用．许多疾病都涉及到FXR1表达的改变．为了了解FXR1P与CMAS(胞嘧啶单核苷酸-N-乙酰神经氨酸合成酶)相互作用所产生的的生物学效应,我们构建了FXR1的过表达载体,并观察其在PC12细胞(大鼠鼠肾上腺嗜铬细胞瘤细胞)和VSMC(血管平滑肌细胞)中的表达以及继而对于细胞形态和CMAS活性相关的许多细胞指标的效应．我们证实,FXR1基因的过表达可以提高PC12细胞中CMAS的活性,并对于该类细胞的生长提供一定程度的保护作用．PC12细胞是一种较为常见的用于研究神经系统疾病的细胞系．结论：我们推测FXR1P是一个组织特异调节因子,可以改变PC12细胞而非VSMC细胞中神经节苷酯(GM1)的浓度．     

脆性X智障蛋白FMRP参与DNA损伤应答的机制

脆性X综合征是世界范围内最常见的遗传性智力缺陷,由脆性X智障蛋白(Fragile X mental retardation protein,FMRP)功能缺陷导致,但其致病机制目前仍然所致甚少。中国科学院遗传与发育生物学研究所张永清研究员研究组和大连医科大学肿瘤干细胞研究院秘晓林教授研究团队密切合作发现FMRP参与调节DNA损伤应答的机制。     

应用多聚酶链式反应快速分析FMR-1基因突变

为了建立一种在先天性智力低下患儿中快速分析脆性X综合征智力低下基因1(Fragile X mental retardation gene 1.FMR-1)突变的方法,对先天性智力低下儿童进行脆性X综合征的大面积筛查和诊断,应用复式多聚酶链式反应一次性扩增FMR-1基因的(CGG)n的重复区,分析CGG重复序列的大小,判断FMR-1基因状态(正常、突变前、突变后),对脆性X综合征可疑患儿快速筛查,在113倒不明原因的先天性智力低下患儿中,分析有脆性X综合征携带者(FMR-1基因前突变者)7例(2男5女),脆性X综合征患者(FMR-1基因突变者)5例,应用多聚酶链式反应可以对脆性X综合征可疑患儿进行大面积初筛,确定携带者和患者。     

The fragile X syndrome: exploring its molecular basis and seeking a treatment

Fragile X syndrome (FXS) - the leading cause of inherited mental retardation - is an X-linked disease caused by loss of expression of the FMR1 (fragile X mental retardation 1) gene. In addition to impairment of higher-cognitive functions, FXS patients show a variety of physical and other mental abnormalities. FMRP, the protein encoded by the FMR1 gene, is thought to play a key role in translation, trafficking and targeting of mRNA in neurons. To better understand FMRP's functions, the protein partners and mRNA targets that interact with FMRP have been sought. These and functional studies have revealed links with processes such as cytoskeleton remodelling via the RhoGTPase pathway and mRNA processing via the RNA interference pathway. In this review, we focus on recent insights into the function of FMRP and speculate on how the absence of FMRP might cause the clinical phenotypes seen in FXS patients. Finally, we explore potential therapies for FXS.     

From FMRP Function to Potential Therapies for Fragile X Syndrome

Fragile X syndrome (FXS) is caused by mutations in the fragile X mental retardation 1 (FMR1) gene. Most FXS cases occur due to the expansion of the CGG trinucleotide repeats in the 5′ un-translated region of FMR1, which leads to hypermethylation and in turn silences the expression of FMRP (fragile X mental retardation protein). Numerous studies have demonstrated that FMRP interacts with both coding and non-coding RNAs and represses protein synthesis at dendritic and synaptic locations. In the absence of FMRP, the basal protein translation is enhanced and not responsive to neuronal stimulation. The altered protein translation may contribute to functional abnormalities in certain aspects of synaptic plasticity and intracellular signaling triggered by Gq-coupled receptors. This review focuses on the current understanding of FMRP function and potential therapeutic strategies that are mainly based on the manipulation of FMRP targets and knowledge gained from FXS pathophysiology.     

Fragile x syndrome

Recent data from a national survey highlighted a significant difference in obesity rates in young fragile X males (31%) compared to age matched controls (18%). Fragile X syndrome (FXS) is the most common cause of intellectual disability in males and the most common single gene cause of autism. This X-linked disorder is caused by an expansion of a trinucleotide CGG repeat (>200) on the promotor region of the fragile X mental retardation 1 gene (FMR1). As a result, the promotor region often becomes methylated which leads to a deficiency or absence of the FMR1 protein (FMRP). Common characteristics of FXS include mild to severe cognitive impairments in males but less severe cognitive impairment in females. Physical features of FXS include an elongated face, prominent ears, and post-pubertal macroorchidism. Severe obesity in full mutation males is often associated with the Prader-Willi phenotype (PWP) which includes hyperphagia, lack of satiation after meals, and hypogonadism or delayed puberty; however, there is no deletion at 15q11-q13 nor uniparental maternal disomy. Herein, we discuss the molecular mechanisms leading to FXS and the Prader-Willi phenotype with an emphasis on mouse FMR1 knockout studies that have shown the reversal of weight increase through mGluR antagonists. Finally, we review the current medications used in treatment of FXS including the atypical antipsychotics that can lead to weight gain and the research regarding the use of targeted treatments in FXS that will hopefully have a significantly beneficial effect on cognition and behavior without weight gain.     

Advances in understanding of fragile X pathogenesis and FMRP function,and in identification of X linked mental retardation genes

The fragile X mental retardation syndrome is caused by large methylated expansions of a CGG repeat in the FMR1 gene that lead to the loss of expression of FMRP, an RNA-binding protein. FMRP is proposed to act as a regulator of mRNA transport or translation that plays a role in synaptic maturation and function. The recent observations of unexpected phenotypes in some carriers of fragile X premutations suggest a pathological role, in these individuals, of an abnormal FMR1 mRNA. FMRP was recently shown to interact preferentially with mRNAs containing a G quartet structure. Mouse and Drosophila models are used to decipher the function of FMRP, which was found to inhibit translation of some mRNA targets, but may be stimulatory in other cases. Proteins interacting with FMRP have been identified, and suggest a link with the Rac1 GTPase pathway that is important in neuronal maturation. Recent advances also include identification of other genes implicated in X-linked mental retardation.     

Comprehensive Analysis of Ultrasonic Vocalizations in a Mouse Model of Fragile X Syndrome Reveals Limited, Call Type Specific Deficits

Fragile X syndrome (FXS) is a well-recognized form of inherited mental retardation, caused by a mutation in the fragile X mental retardation 1 (Fmr1) gene. The gene is located on the long arm of the X chromosome and encodes fragile X mental retardation protein (FMRP). Absence of FMRP in fragile X patients as well as in Fmr1 knockout (KO) mice results, among other changes, in abnormal dendritic spine formation and altered synaptic plasticity in the neocortex and hippocampus. Clinical features of FXS include cognitive impairment, anxiety, abnormal social interaction, mental retardation, motor coordination and speech articulation deficits. Mouse pups generate ultrasonic vocalizations (USVs) when isolated from their mothers. Whether those social ultrasonic vocalizations are deficient in mouse models of FXS is unknown. Here we compared isolation-induced USVs generated by pups of Fmr1-KO mice with those of their wild type (WT) littermates. Though the total number of calls was not significantly different between genotypes, a detailed analysis of 10 different categories of calls revealed that loss of Fmr1 expression in mice causes limited and call-type specific deficits in ultrasonic vocalization: the carrier frequency of flat calls was higher, the percentage of downward calls was lower and that the frequency range of complex calls was wider in Fmr1-KO mice compared to their WT littermates.